Veuillez utiliser cette adresse pour citer ce document :
https://di.univ-blida.dz/jspui/handle/123456789/24747
Affichage complet
Élément Dublin Core | Valeur | Langue |
---|---|---|
dc.contributor.author | KERRACHE, Hamza | - |
dc.contributor.author | ZAROUTA, Mohamed Yacine | - |
dc.contributor.author | FLITI, Mohamed Oualid | - |
dc.contributor.author | BOUDJELLA., ML.(Promoteur) | - |
dc.date.accessioned | 2023-06-13T13:23:23Z | - |
dc.date.available | 2023-06-13T13:23:23Z | - |
dc.date.issued | 2022 | - |
dc.identifier.uri | https://di.univ-blida.dz/jspui/handle/123456789/24747 | - |
dc.description | MPHA 651 | fr_FR |
dc.description.abstract | Quelques cas de thrombocytopénie et d'événements thrombotiques ressemblant au SAPL ont été signalés chez des receveurs de vaccins contre la COVID-19 à base de vecteur adénoviral. Cependant, l’association des aPL avec la vaccination COVID-19 n'est pas claire. Dans notre étude la comparaison entre les 03 groupes : sujets atteins de COVID-19 (n=106), sujets vaccinés (n=38) et témoins sains (n=70), a montré des taux d’aPL : 40%, 84% et 19% respectivement. Nous avons constaté des valeurs hautement significatives des taux d’aPL : chez les patients COVID-19 vs témoins (p=0.005/ OR=2.88), vaccinés vs témoins (p=10 -10 /OR=18.63), vaccinés vs patients atteints de COVID (p=10 -5 /OR=6.48). Les sujets atteints de COVID-19 ont montré des valeurs statistiquement significatives en positivité des Ac anti-B2GP1 IgM par rapport aux vaccinés et des témoins sains (p=0.004, p=0.015 respectivement). Alors que les sujets vaccinés ont montré des valeurs statistiquement très hautement significatives en positivité d’aCL IgM par rapport à la population des patients atteints de COVID-19 et des témoins sains (p=10 -9 , p=10 -12 respectivement). Ces considérations suggèrent que les aPL peuvent représenter un facteur de risque d'événements thrombotiques après la vaccination contre le COVID-19 et méritent des investigations supplémentaires. Abstract :A few cases of thrombocytopenia and APS-like thrombotic events have been reported in recipients of adenoviral vector-based COVID-19 vaccines. However, the association of aPL with COVID-19 vaccination is unclear. In our study, the comparison between the 03 groups: COVID-19 patients (n=106), vaccine receivers (n=38) and healthy controls (n=70), showed aPL rates at : 40%, 84 % and 19% respectively. We found highly significant values of aPL levels: in COVID-19 patients vs healthy controls (p=0.005/OR=2.88), vaccine receivers vs healthy controls (p=10-10 /OR=18.63), vaccine receivers vs COVID-19 patients (p=10-5/OR=6.48). COVID-19 patients showed statistically significant values in anti-B2GP1 IgM positivity compared to vaccine receivers and healthy controls (p=0.004, p=0.015 respectively). While vaccine receivers showed very highly statistically significant values in aCL IgM positivity compared to COVID-19 patients and healthy controls (p=10-9, p=10-12 respectively). These considerations suggest that aPL may represent a risk factor for thrombotic events after COVID-19 vaccination and warrant further investigations. | fr_FR |
dc.language.iso | fr | fr_FR |
dc.publisher | Université de Blida 1, Faculté de Medecine | fr_FR |
dc.subject | A few cases of thrombocytopenia and APS-like thrombotic events have been reported in recipients of adenoviral vector-based COVID-19 vaccines. However, the association of aPL with COVID-19 vaccination is unclear. In our study, the comparison between the 03 groups: COVID-19 patients (n=106), vaccine receivers (n=38) and healthy controls (n=70), showed aPL rates at : 40%, 84 % and 19% respectively. We found highly significant values of aPL levels: in COVID-19 patients vs healthy controls (p=0.005/OR=2.88), vaccine receivers vs healthy controls (p=10-10 /OR=18.63), vaccine receivers vs COVID-19 patients (p=10-5/OR=6.48). COVID-19 patients showed statistically significant values in anti-B2GP1 IgM positivity compared to vaccine receivers and healthy controls (p=0.004, p=0.015 respectively). While vaccine receivers showed very highly statistically significant values in aCL IgM positivity compared to COVID-19 patients and healthy controls (p=10-9, p=10-12 respectively). These considerations suggest that aPL may represent a risk factor for thrombotic events after COVID-19 vaccination and warrant further investigations. | fr_FR |
dc.subject | COVID-19 vaccine - anti phospholipid antibodies – anticardiolipin - anti-ß2 GPI | fr_FR |
dc.title | Les anticorps anti phospholipides chez les sujets vaccinés contre la COVID-19 | fr_FR |
dc.type | Thesis | fr_FR |
Collection(s) : | Mémoires |
Fichier(s) constituant ce document :
Fichier | Description | Taille | Format | |
---|---|---|---|---|
Memoir vaccin final à imprimer.pdf | MPHA 651 | 6,16 MB | Adobe PDF | Voir/Ouvrir |
Tous les documents dans DSpace sont protégés par copyright, avec tous droits réservés.